Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone

Effects of 3-aminobenzamide on ventricular function in infarct heart assessed by quantitative tissue velocity imaging

(2016) Man Wang et al.   Journal of Cardiovascular Medicine

Mammalian Base Excision Repair: Functional Partnership between PARP-1 and APE1 in AP-Site Repair

(2015) Rajendra Prasad et al.   PLoS One

The age factor for mitoxantrone’s cardiotoxicity: Multiple doses render the adult mouse heart more susceptible to injury

(2015) José Luís Dores-Sousa et al.   TOXICOLOGY

Poly(ADP-ribose): A signaling molecule in different paradigms of cell death

(2014) Francesca Aredia et al.   BIOCHEMICAL PHARMACOLOGY

Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity

(2014) S. Khiati et al.   CLINICAL CANCER RESEARCH

Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment

(2014) Y. Zhao et al.   FREE RADICAL BIOLOGY AND MEDICINE

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

(2014) Yoshihiko Ichikawa et al.   JOURNAL OF CLINICAL INVESTIGATION

Prevention of Anthracycline-Induced Cardiotoxicity

(2014) Pimprapa Vejpongsa et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Drug-Induced Conformational Population Shifts in Topoisomerase-DNA Ternary Complexes

(2014) Nan-Lan Huang et al.   MOLECULES

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

(2014) Tomáš Šimůnek et al.   Pharmacological Reports

The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity

(2013) Luciana Grazziotin Rossato et al.   ARCHIVES OF TOXICOLOGY

Mitochondrial Cumulative Damage Induced by Mitoxantrone: Late Onset Cardiac Energetic Impairment

(2013) Luciana Grazziotin Rossato et al.   Cardiovascular Toxicology

Therapeutic Concentrations of Mitoxantrone Elicit Energetic Imbalance in H9c2 Cells as an Earlier Event

(2013) Luciana Grazziotin Rossato et al.   Cardiovascular Toxicology

The Heart As a Target for Xenobiotic Toxicity: The Cardiac Susceptibility to Oxidative Stress

(2013) Vera Marisa Costa et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline-Induced Cardiotoxicity

(2013) P Vejpongsa et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The expanding role of PARPs in the establishment and maintenance of heterochromatin

(2013) Françoise Dantzer et al.   FEBS Journal

Subclinical Myocardial Dysfunction in Multiple Sclerosis Patients Remotely Treated With Mitoxantrone: Evidence of Persistent Diastolic Dysfunction

(2013) Emer Joyce et al.   JOURNAL OF CARDIAC FAILURE

Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy

(2013) Filipa S. Carvalho et al.   MEDICINAL RESEARCH REVIEWS

Poly(ADP-ribose): PARadigms and PARadoxes

(2013) Alexander Bürkle et al.   MOLECULAR ASPECTS OF MEDICINE

On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs

(2013) Chyuan-Chuan Wu et al.   NUCLEIC ACIDS RESEARCH

Drugging Topoisomerases: Lessons and Challenges

(2012) Yves Pommier   ACS Chemical Biology

Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells

(2012) Natisha Magan et al.   ANTI-CANCER DRUGS

Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection

(2012) Martin Štěrba et al.   ANTIOXIDANTS & REDOX SIGNALING

Mitochondria as a Source of Reactive Oxygen and Nitrogen Species: From Molecular Mechanisms to Human Health

(2012) Tiago R. Figueira et al.   ANTIOXIDANTS & REDOX SIGNALING

Anthracenedione–methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles

(2012) Chieh-Hua Lee et al.   BIOCHEMICAL PHARMACOLOGY

Abstract LB-339: Cause of death in cancer survivors

(2012) Y. Ning et al.   CANCER RESEARCH

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases

(2012) V. M. Costa et al.   CURRENT MEDICINAL CHEMISTRY

Application of Fenton, photo-Fenton, solar photo-Fenton, and UV/H2O2 to degradation of the antineoplastic agent mitoxantrone and toxicological evaluation

(2012) Rodrigo Pereira Cavalcante et al.   ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH

Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies

(2012) Yanti Octavia et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats

(2011) V. Ashutosh Rao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Unraveling the Biological Roles of Reactive Oxygen Species

(2011) Michael P. Murphy et al.   Cell Metabolism

Proteomic insights into chronic anthracycline cardiotoxicity

(2011) Martin Štěrba et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

(2011) M. Ali et al.   MOLECULAR CANCER THERAPEUTICS

Cardiovascular effects of systemic cancer treatment

(2010) Elżbieta Senkus et al.   CANCER TREATMENT REVIEWS

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer

(2010) C. M. Annunziata et al.   CLINICAL CANCER RESEARCH

Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype

(2010) H Gréen et al.   PHARMACOGENOMICS JOURNAL

Cross-Talk Between Mitochondria and NADPH Oxidase: Effects of Mild Mitochondrial Dysfunction on Angiotensin II-Mediated Increase in Nox Isoform Expression and Activity in Vascular Smooth Muscle Cells

(2009) João Wosniak et al.   ANTIOXIDANTS & REDOX SIGNALING

Cardiomyocyte death in doxorubicin-induced cardiotoxicity

(2009) Yi-Wei Zhang et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis

(2009) S. Cotte et al.   BRAIN

Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells

(2009) Jenifer Saffi et al.   DNA REPAIR

EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary

(2009) Milena Sant et al.   EUROPEAN JOURNAL OF CANCER

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

(2009) Garrett M. Morris et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Oxidative Stress and Mitochondrial DNA Damage in Heart Failure

(2008) Hiroyuki Tsutsui et al.   CIRCULATION JOURNAL

Cell Death in Heart Failure

(2008) Kazuhiko Nishida et al.   CIRCULATION JOURNAL

Molecular Recognition Models: A Challenge to Overcome

(2008) Rafael Caceres et al.   CURRENT DRUG TARGETS

The expanding field of poly(ADP-ribosyl)ation reactions. ‘Protein Modifications: Beyond the Usual Suspects’ Review Series

(2008) Antoinette Hakmé et al.   EMBO REPORTS

The wanderings of a free radical

(2008) Barry Halliwell   FREE RADICAL BIOLOGY AND MEDICINE

WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: Identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers

(2007) Che-Jen Hsiao et al.   BIOCHEMICAL PHARMACOLOGY